382

Search

Incuron, LLC

Russian Pharmaceutical Company Incuron, LLC was created in January 2010 by private mutual fund with high-risk (venture) investments «Bioprocess Capital Ventures» (onward «Fund») cooperative with American Public Company «Cleveland Biolabs, Inc.»

Incuron Announces Updates on Clinical Progress with CBL0137

09.02.2015 Incuron, a joint subsidiary of the Bioprocess Capital Ventures closed-end investment fund and Cleveland BioLabs, Inc., announced updates on clinical progress with lead oncology p

Incuron, LLC Announces the Successful Completion of a Phase 1 Study of CBL0102

15.01.2012 Incuron, LLC Announces the Successful Completion of a Phase 1 Study of CBL0102 Incuron, a joint subsidiary of the Bioprocess Capital Ventures closed-end investment fund and Clev

Incuron, LLC Announces Start of US Trial With CBL0137

The primary objective of the study is to determine the maximally tolerated dose and recommend a Phase 2 dose for CBL0137 in these patients. Secondary objectives include describing the dose l

Latest news

Incuron Announce Notice of Allowance from FDA to Commence Clinical Testing with CBL0137.

04.04.2012 Incuron, a joint subsidiary of the Bioprocess Capital Ventures closed-end investment fun

Incuron Announces Updates on Clinical Progress with CBL0137

09.02.2015 Incuron, a joint subsidiary of the Bioprocess Capital Ventures closed-end investment fun

Incuron, LLC Announces Start of US Trial With CBL0137

The primary objective of the study is to determine the maximally tolerated dose and recommend a Phas

Incuron Announces Updates on Clinical Progress with CBL0137

09.02.2015 Incuron, a joint subsidiary of the Bioprocess Capital Ventures closed-end investment fun

Incuron, LLC Announces the Successful Completion of a Phase 1 Study of CBL0102

15.01.2012 Incuron, LLC Announces the Successful Completion of a Phase 1 Study of CBL0102 Incuron,

Incuron Announce Start of Phase 1 Trial for CBL0137

The trial is being conducted at five leading oncology centers in the Russian Federation. The primary

With the support of the innovation center Skolkovo

Aboute us

Incuron, LLC is a Russian Federation based joint venture founded in January 2010 between Russian Closed Mutual Venture Fund "Bioprocess Capital Ventures" (hereinafter "Fund"), and Cleveland BioLabs.

Incuron, LLC is developing an innovative pipeline of drugs to treat oncology and autoimmune disease for the global markets. Incuron's research and development operations include activities in both the Russian Federation and the U.S.

Video

You are here:   HomeHome